All Children’s hospital will make “big changes” after heart unit scandal

Johns Hopkins All Children’s Hospital, based in St. Petersburg, Fla., is making big changes in the fallout of investigations from the Tampa Bay Times that its pediatric heart surgery unit had an unusually high mortality rate. The publication also uncovered other serious problems with the hospital’s procedures that led to a CMS investigation.

Since then, several hospital executives resigned, and the facility has had to meet new patient safety and quality metrics and work with CMS to continue being a qualified provider.

In addition, the hospital is undertaking other “sweeping” changes, the TBT reported at the end of June. The changes include new evaluations for top executives, including checks and balances on the hospital’s president, better tracking of internal complaints, thorough vetting of doctors, and other safety and quality metrics, according to the TBT.

The changes are partly prompted from an investigation from law firm Gibson Dunn, which Johns Hopkins Medicine hired to investigate the hospital. The firm filed a report, and Johns Hopkins has released a 12-page memo with recommendations to improve.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.